Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from microdissection isolated epthelium and stroma of the same pateint with benign prostatic hyperplasia

ABSTRACT: Although there are great differences between hyperplastic epithelium and stroma, so far, no data show differences in gene expression between epithelium and stroma, which may have a potential great impact on the discovery of drug targets We performed the microdissection and microarray to uncover the differences in gene expression between epithelium and stroma of the same patient with BPH

ORGANISM(S): Homo sapiens

PROVIDER: GSE183523 | GEO | 2021/09/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

iTRAQ-based LC-MS/MS analysis of benign prostatic hyperplasia prostate tissues with different stroma/epithelium ratio

Project description:To investigate proteins potentially involved in the survival of prostate epithelial cells, we initially collected prostate tissues from 32 BPH patients. Subsequently, we conducted immunohistochemistry (IHC) staining using an anti-alpha-smooth muscle actin (α-SMA) antibody, recognized as a marker for smooth muscle cells and myofibroblasts. We delineated the areas of the stroma, glandular epithelium, and glandular lumen based on this staining. We digitized and conducted subsequent analysis of the relative percentage of different tissue components, including the stroma/epithelium ratio (S/E). Specimens were ranked based on the S/E ratio, leading to the categorization of the 9 specimens with the lowest S/E into group 1 (Epithelium-hi), where the epithelial components may have more significant roles in BPH development. Conversely, the 9 specimens with the highest S/E were placed in group 2 (Epithelium-lo). Within each group, we further subdivided them into 3 subgroups labeled as A through E. Subsequently, we employed isobaric tags for relative and absolute quantitation (iTRAQ)-based liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify the differentially expressed proteins (DEPs) between the two main groups.

2024-01-24 | PXD048857 |

Different expressed genes in epithelium and stromal of Benign Prostatic Hyperplasia

2011-08-10 | GSE31323 | GEO

Different expressed genes in epithelium and stromal of Benign Prostatic Hyperplasia

Project description:To identify the genes differently expressed in the epithelium and the stromal of Benign Prostatic Hyperplasia (BPH), we collect the epithelium and the stromal from the patients with benign prostatic hyperplasia by laser micro-dissection. And then, Affymetrix HG-U133_Plus_2 gene-chip was used to detect and compare the expression level of genes. To find which genes are most abundantly expressed in epithelium and stromal and what is the role of these genes in the pathogenesis of BPH. 8 prostate tissues were collected from patients undergone transurethral resection of the prostate (TURP) with informed consent. Each tissue was embedded in O.C.T and subsequently used for laser micro-dissection. The total RNA was isolated from each sample and equally mixed for gene-chip assay.

2011-08-09 | E-GEOD-31323 | biostudies-arrayexpress

Genome-wide analysis of prostatic tissue gene expression from patients with benign prostatic hyperplasia

Project description:Analysis of gene expression in prostatic tissue from BPH patients with and without SRD5A2 gene methylation. The hypothesis is that BPH patients with DNA methylation of the SRD5A2 gene promoter have impaired conversion of testosterone to dihydrotestosterone, and therefore may use an alternative signaling pathway for prostatic tissue growth. Here, we compare gene expression profiles of SRD5A2-methylated vs. unmethylated prostatic tissue to nominate alternative biological pathways relevant in each molecular subtype of BPH.

2017-10-01 | GSE101486 | GEO

Copy number analysis of BPH (Benign Prostatic Hyperplasia)

Project description:BPH samples harbored minimal copy number alterations, and the fraction of altered genome was far lower than primary prostate cancer and other neoplastic diseases.

2020-03-18 | GSE124187 | GEO

Expression data from benign prostatic hyperplasia samples and normal controls

Project description:To further development of our gene expression signature for benign prostatic hyperplasia, we conducted expression profiles of BPH and normal samples.

2020-05-28 | GSE119195 | GEO

Multi-omic diagnostics of prostate cancer in the presence of benign prostatic hyperplasia

Project description:There is an unmet need for improved diagnostic testing and risk prediction for cases of prostate cancer (PCa) to improve care and reduce overtreatment of indolent disease. Here we have analysed the serum proteome and lipidome of 262 study participants by liquid chromatography-mass spectrometry, including participants with a diagnosis of PCa, benign prostatic hyperplasia (BPH), or otherwise healthy volunteers, with the aim of improving biomarker specificity. Although a two-class machine learning model was able to separate PCa from controls with sensitivity of 0.82 and specificity of 0.95, adding BPH resulted in a statistically significant decline in specificity for prostate cancer to 0.76, with half of BPH cases being misclassified by the model as PCa. A small number of biomarkers differentiating between BPH and prostate cancer were identified, including proteins in MAP Kinase pathways, as well as in lipids containing oleic acid; these may offer a route to greater specificity. These results highlight, however, that whilst there are opportunities for machine learning, these will only be achieved by use of appropriate training sets that include confounding comorbidities, especially when calculating the specificity of a test.

2024-01-26 | PXD046530 | Pride

Transcription profiling of doxazosin response, an alpha(1)-adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH)

Project description:BACKGROUND: We used cDNA microarray analysis to obtain insights into the mechanisms of action of doxazosin, an alpha(1)-adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH). METHODS: Hierarchical clustering analysis and significance analysis of microarray (SAM) were performed to identify genes differentially expressed between untreated stromal cells cultured from normal tissue and BPH, and changes in gene expression induced by doxazosin. Transcript levels of selected genes were validated by real-time reverse-transcription polymerase chain reaction (RT-PCR). RESULTS: Hierarchical clustering analyses separated untreated normal and BPH cells. Sixty-seven genes whose expression varied at least twofold after doxazosin treatment in both normal and BPH cells were identified, as were 93 genes differentially regulated in normal versus BPH cells. Molecular targets consistent with tumor necrosis factor (TNF)-alpha-related activity were identified. CONCLUSIONS: Normal versus BPH stromal cells differ in global gene transcription. Doxazosin induced gene expression changes relevant to proliferation/apoptosis, immune defense, cell-cell signaling/signal transduction, and transcriptional regulation.

2005-11-07 | E-SMDB-2934 | biostudies-arrayexpress

Expression data from microdissection isolated epthelium and stroma of the same pateint with benign prostatic hyperplasia

Project description:Expression data from microdissection isolated epthelium and stroma of the same pateint with benign prostatic hyperplasia

| PRJNA761117 | ENA

High Throughput Sequencing of a Mouse Model for Benign Prostatic Hyperplasia (BPH)

Project description:The goal of this study is to identify genes of interest through high throughput sequencing of a mouse model for BPH and compare with control, WT mice. Additionally, to use the generated RNA expression profile to compare with a previously established human microarray for BPH. Through these comparisons we hope to identify novel genes contributing to the disease in humans. Specific results of these analyses are in progress and publication content is yet to be determined.

2023-01-22 | GSE167196 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data